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In this issue of Journal of General Virology (JGV), we publish a manuscript by Kwon and colleagues 
describing a novel mutation in the neuraminidase (NA) gene of the 2009 pandemic H1N1 influenza 
A virus (IAV) that confers cross-resistance to all clinically approved 
neuraminidase inhibitors (NAI) (insert hyperlink to article). During the evaluation of this  
manuscript for publication in JGV, the description of a multidrug-resistant IAV raised concerns 
regarding potential for dual-use research of concern (DURC). However, after careful 
consideration we decided to publish this article and here, we discuss the benefits and risks 
associated with the work and outline our decision process. 
The authors employed a virus library that was generated by extensive mutagenesis of the NA 
coding region starting with an Oseltamivir-resistant variant (NA H275Y) of the 2009 pandemic IAV 
strain A/California/04/2009. The virus library was passaged in the presence of increasing 
concentrations of Zanamivir and the selected viruses were identified by sequencing. This approach 
identified a novel mutation, N436I, which was found to confer cross-resistance to all NAI, either 
alone or in combination with H275Y. Notably, analysis of viral growth characteristics showed that a 
virus carrying the N436I mutation was not attenuated in vitro or in vivo. In contrast, the double 
mutant H275Y/N436I was attenuated in embryonated chicken eggs, MDCK cells and in mice. 
Transmission experiments in ferrets further revealed that the single mutant was transmitted by direct 
contact as well as respiratory droplet transmission. Thus, the authors have identified a novel 
mutation in NA that confers cross-resistance to all NAI at no apparent fitness costs. Importantly, the 
N436I mutation has never been identified in natural isolates of IAV. It can thus be argued that N436 
is highly conserved and selection of N436I requires an existing Oseltamivir resistance mutation 
(H275Y) plus Zanamivir treatment. While this might limit the chances for the N436I mutation to 
occur it is still unclear why it has never been found in nature, given the observed lack of fitness 
costs. This in itself is an important observation that is worth following up, another reason we decided 
publication was warranted.  
In addition to NAIs, inhibitors of the viral ion channel M2are also available for the treatment of 
influenza. However, due to almost complete resistance of the circulating human strains of IAV, M2 
inhibitors are no longer recommended [1, 2]. Thus, the only treatment options remaining at present 
are the NAI that comprise four clinically approved drugs, namely Oseltamivir, Zanamivir, Peramivir 
and Laninamivir. At present, mutations that confer resistance to NAI are detected in less than 1% of 
human isolates and mutations that lead to cross-resistance are very rare [3, 4]. However, such 
mutations are observed typically in immunocompromised patients in which IAV has the capability to 
replicate continually even during treatment with multiple NAIs [3, 5]. Thus far, reports on the 
replication characteristics and pathogenicity of such viruses have suggested that cross-resistance 
comes at substantial fitness costs [6, 7]. 
The current study challenges this assumption, and we therefore believe that this is an important 
contribution to knowledge about antiviral strategies for influenza treatment. It might stimulate work in 
the field to evaluate further the potential for cross-resistance at low or minimal fitness cost. In 
particular, studies on the selection of such variants will help us to estimate the likelihood that such 
viruses could arise in the future. Furthermore, the identification of the variant N436I can also inform 
public surveillance efforts for drug resistance so that appearance of N436I variants would be 
detected early on. 
Given the potential concerns to generate a multidrug-resistant strain of IAV the authors took several 
measures to mitigate risks. First, the authors generated the drug-resistant viruses in the background 
of pandemic 2009 H1N1 strain A/California/04/2009, to which the worldwide population has strong 
immunity. Second, the authors tested that the N436I mutant did not vary antigenically from its 
parental strain and is thus still neutralized by sera elicited with the current H1N1 vaccine. Third, the 
work with the NAI-resistant viruses was performed in a biosafety level  
3 laboratory. 
When this manuscript was evaluated for its suitability for publication in JGV, the question was raised 
whether this work represents DURC. In response to these concerns, additional reviewers were 
asked to evaluate the manuscript with a particular focus on the DURC potential. Moreover, the 
manuscript was discussed by JGV editors to decide whether the risks associated with publishing 
this work could outweigh the benefits. First, it was debated whether generation of the multidrug-
resistant virus in the H1N1 background by people who seek to do harm or accidental release of this 
virus would pose a substantial risk. On this matter, a clear consensus was reached that this is not 
the case as the worldwide population has developed immunity to the 2009 pandemic virus and the 
authors clearly show that the multidrug-resistant virus is neutralized by antibodies elicited by the 
current H1N1 vaccine. Second, it was discussed whether this study facilitates the generation of 
multidrug-resistant influenza viruses of novel subtypes, such as H5N1 or H7N9, which could be 
exploited for malintent. Previous studies have shown that mutations conferring resistance to NAI in 
one subtype of NA do not necessarily confer NAI resistance in other subtypes [8, 9]. Furthermore, 
the impact of the resistance mutation on virulence can also vary between different viral backgrounds 
[6, 7]. Importantly, methods used to select for resistant viruses have been known for many years 
and are well described in the literature. Therefore, we concluded that the knowledge described here 
provides an incremental advancement on how to generate a multidrug-resistant IAV in an 
antigenically novel background for those who might seek to do harm. Based on the important 
benefits of this work, the negligible risk of the virus and our extensive and considered deliberations 
we decided to move forward with publication. 
By explaining the decision process and the discussions that were held to assess the benefits and 
the risks associated with the work by Kwon et al. we aim to facilitate the ongoing dialogue
between proponents and opponents of this type of work, ensure transparency and help basic 
science move forward. JGV is dedicated to responsible publication and supports efforts in the field 
of virus research to answer important questions in the safest way possible. As JGV is published by 
the Microbiology Society, our decision is also consistent with the Society position statement on 
DURC (https://microbiologysocietv.org/publication/position-statement/2014- biosecurity-and-the-
dual-use-of-research.html). 
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